Solubilized deoxycholic acid has been FDA-approved and used commercially for local fat reduction. However, injection site reactions, commonly bruising and swelling, have limited its success in the clinic. Deoxycholate-based composite microparticles can decrease treatment-associated inflammation via controlled drug release to mitigate these side effects. Here, we report that optimizing particle dosage can significantly reduce fat in a mouse model without causing any visible injection site reactions. The deoxycholate microparticle treatment significantly reduces fat, while the inflammation resolves by 4 weeks postinjection. Additional treatments after inflammation resolution cause significant further fat reduction with a similar resolution timeframe. We also demonstrate the scalability of the particle treatment by modulating the number of injection sites to achieve a well-tolerated, significant fat reduction in a larger rodent model. Overall, deoxycholate-based composite microparticles effectively reduce fat in a well-tolerated manner, showing its potential for future clinical application.
Get full access to this article
View all access options for this article.
References
1.
SarwerDB, CrerandCE. Body image and cosmetic medical treatments. Body Image, 2004; 1(1):99–111; doi: 10.1016/S1740-1445(03)00003-2
AbdelaalM, Le RouxCW, DochertyNG. Morbidity and mortality associated with obesity. Ann Transl Med, 2017; 5(7):161; doi: 10.21037/atm.2017.03.107
4.
HuizingaGP, SingerBH, SingerK. The Collision of Meta-Inflammation and SARS-CoV-2 Pandemic Infection. Endocrinology, 2020; 161(11); doi: 10.1210/endocr/bqaa154
5.
QuittkatHL, HartmannAS, DüsingR, et al.Body dissatisfaction, importance of appearance, and body appreciation in men and women over the lifespan. Front Psychiatry, 2019; 10:864; doi: 10.3389/fpsyt.2019.00864
6.
BaumannL, ShridharaniSM, HumphreyS, et al.Personal (Self) perceptions of submental fat among adults in the United States. Dermatol Surg, 2019; 45(1):124–130; doi: 10.1097/DSS.0000000000001648
7.
ThomasWW, BloomJD. Neck contouring and treatment of submental adiposity. J Drugs Dermatol, 2017; 16(1):54–57.
8.
MordonS, PlotE. Laser lipolysis versus traditional liposuction for fat removal. Expert Rev Med Devices, 2009; 6(6):677–688.
9.
GaribyanL, SipprellWH, JalianHR, et al.Three‐dimensional volumetric quantification of fat loss following cryolipolysis. Lasers Surg Med, 2013; 46(2):75–80.
10.
MulhollandRS, PaulMD, ChalfounC. Noninvasive body contouring with radiofrequency, ultrasound, cryolipolysis, and low-level laser therapy. Clin Plast Surg, 2011; 38(3):503–520.
11.
DuncanD, RotundaAM. Injectable therapies for localized fat loss: State of the art. Clin Plast Surg, 2011; 38(3):489–501, vii; doi: 10.1016/j.cps.2011.02.005
12.
KennedyJ, VerneS, GriffithR, et al.Non‐invasive subcutaneous fat reduction: A review. J Eur Acad Dermatol Venereol, 2015; 29(9):1679–1688.
13.
PereiraJ, CavalcanteY, WanzelerR. The role of inflammation in adipocytolytic nonsurgical esthetic procedures for body contouring. Clin Cosmet Investig Dermatol, 2017; 10:57–66; doi: 10.2147/CCID.S125580
14.
AscherB, FellmannJ, MonheitG. ATX-101 (deoxycholic acid injection) for reduction of submental fat. Expert Rev Clin Pharmacol, 2016; 9(9):1131–1143; doi: 10.1080/17512433.2016.1215911
15.
DeeksED. Deoxycholic acid: A review in submental fat contouring. Am J Clin Dermatol, 2016; 17(6):701–707; doi: 10.1007/s40257-016-0231-3
16.
WalkerP, LeeD. A phase 1 pharmacokinetic study of ATX‐101: Serum lipids and adipokines following synthetic deoxycholic acid injections. J Cosmet Dermatol, 2015; 14(1):33–39; doi: 10.1111/jocd.12122
17.
ThuangtongR, BentowJJ, KnoppK, et al.Tissue-selective effects of injected deoxycholate. Dermatol Surg, 2010; 36(6):899–908; doi: 10.1111/j.1524-4725.2010.01566.x
18.
LindhorstA, RaulienN, WieghoferP, et al.Adipocyte death triggers a pro-inflammatory response and induces metabolic activation of resident macrophages. Cell Death Dis, 2021; 12(6):579; doi: 10.1038/s41419-021-03872-9
19.
ParkJ, SohnJH, HanSM, et al.Adipocytes are the control tower that manages adipose tissue immunity by regulating lipid metabolism. Front Immunol, 2020; 11:598566; doi: 10.3389/fimmu.2020.598566
20.
Schuller-PetrovicS, WölkartG, HöflerG, et al.Tissue-toxic effects of phosphatidylcholine/deoxycholate after subcutaneous injection for fat dissolution in rats and a human volunteer. Dermatol Surg, 2008; 34(4):529–543; doi: 10.1111/j.1524-4725.2008.34128.x
21.
CohenJL, ChenDLK, GreenJB, et al.Additional thoughts on the new treatment Kybella. Semin Cutan Med Surg, 2015; 34(3):138–139; doi: 10.12788/j.sder.2015.0175
22.
FarinaGA, CherubiniK, De FigueiredoMAZ, et al.Deoxycholic acid in the submental fat reduction: A review of properties, adverse effects, and complications. J Cosmet Dermatol, 2020; 19(10):2497–2504; doi: 10.1111/jocd.13619
23.
SafariH, KaczorowskiN, FelderML, et al.Biodegradable, bile salt microparticles for localized fat dissolution. Sci Adv, 2020; 6(49); doi: 10.1126/sciadv.abd8019
24.
MoghimiSM, ParhamifarL, AhmadvandD, et al.Particulate systems for targeting of macrophages: Basic and therapeutic concepts. J Innate Immun, 2012; 4(5-6):509–528; doi: 10.1159/000339153
25.
ChampionJA, MitragotriS. Role of target geometry in phagocytosis. Proc Natl Acad Sci, 2006; 103(13):4930–4934; doi: 10.1073/pnas.0600997103
26.
SafariH, KelleyWJ, SaitoE, et al.Neutrophils preferentially phagocytose elongated particles—An opportunity for selective targeting in acute inflammatory diseases. Sci Adv, 2020; 6(24):eaba1474; doi: 10.1126/sciadv.aba1474
27.
VargheseM, GriffinC, McKernanK, et al.Sex differences in inflammatory responses to adipose tissue lipolysis in diet-induced obesity. Endocrinology, 2019; 160(2):293–312; doi: 10.1210/en.2018-00797
28.
RotundaAM, SuzukiH, MoyRL, et al.Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution. Dermatol Surg, 2004; 30(7):1001–1008; doi: 10.1111/j.1524-4725.2004.30305.x
29.
MartinsT, Castro-RibeiroC, LemosS, et al.Murine models of obesity. Obesities, 2022; 2(2):127–147; doi: 10.3390/obesities2020012
30.
IzquierdoAG, CrujeirasAB, CasanuevaFF, et al.Leptin, obesity, and leptin resistance: Where are we 25 years later? Nutrients, 2019; 11(11):2704; doi: 10.3390/nu11112704
31.
Gallou-KabaniC, VigéA, GrossM-S, et al.C57BL/6J and A/J mice fed a high-fat diet delineate components of metabolic syndrome. Obesity, 2007; 15(8):1996–2005; doi: 10.1038/oby.2007.238
32.
HumphreyS, CohenJL, BhatiaAC, et al.Improvements in submental contour up to 3 years after ATX-101: Efficacy and safety follow-up of the phase 3 REFINE trials. Aesthet Surg J, 2021; 41(11):NP1532–NP1539; doi: 10.1093/asj/sjab100
33.
WalkerPS, LeeDR, TothBA, et al.Histological analysis of the effect of ATX-101 (Deoxycholic Acid Injection) on subcutaneous fat: Results from a Phase 1 Open-label study. Dermatol Surg, 2020; 46(1):70–77; doi: 10.1097/DSS.0000000000001851
34.
ChusydDE, WangD, HuffmanDM, et al.Relationships between rodent white adipose fat pads and human white adipose fat depots. Front Nutr, 2016; 3:10.
35.
MestasJ, HughesCCW. Of mice and not men: Differences between mouse and human immunology. J Immunol, 2004; 172(5):2731–2738; doi: 10.4049/jimmunol.172.5.2731
36.
KelleyWJ, FromenCA, Lopez-CazaresG, et al.PEGylation of model drug carriers enhances phagocytosis by primary human neutrophils. Acta Biomater, 2018; 79:283–293; doi: 10.1016/j.actbio.2018.09.001
37.
ShiGH, ConnorRJ, CollinsDS, et al.Subcutaneous injection performance in Yucatan miniature pigs with and without human hyaluronidase and auto-injector tolerability in humans. AAPS PharmSciTech, 2021; 22(1):39; doi: 10.1208/s12249-020-01880-0
38.
JalianHR, FitzgeraldR, BowenB, et al.Submental fat reduction using sequential treatment approach with cryolipolysis and ATX‐101. J Cosmet Dermatol, 2022; 21(6):2437–2444; doi: 10.1111/jocd.14909
39.
BankheadP, LoughreyMB, FernándezJA, et al.QuPath: Open source software for digital pathology image analysis. Sci Rep, 2017; 7(1):16878; doi: 10.1038/s41598-017-17204-5
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
